Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
This study has been completed.
Sponsor:
Sarah Cannon Research Institute
Collaborator:
Genentech
Information provided by:
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT00360360
First received: August 2, 2006
Last updated: May 3, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | March 2009 |
| Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |